Related Experiment Videos
Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME)
Ophthalmic Surgery and Lasers
|November 26, 1999
Summary
Subthreshold diode laser photocoagulation effectively treats diffuse diabetic macular edema (DDME). This invisible laser treatment reduces macular edema and preserves visual fields, offering a promising option for diabetic retinopathy management.
Area of Science:
- Ophthalmology
- Medical Technology
Background:
- Diabetic macular edema (DDME) is a leading cause of vision loss in diabetic patients.
- Conventional photocoagulation can cause visual field defects.
Observation:
- A prospective pilot study evaluated 810 nm subthreshold diode laser modified grid photocoagulation in 50 eyes with DDME.
- Follow-up averaged 14.11 months, with re-treatment for residual edema.
Findings:
- DDME reduction/elimination occurred in 39% of eyes within 6-12 months and 74% within 15-24 months.
- Eighty-eight percent of patients maintained stable vision; visual field tests showed no subjective worsening.
- Systemic hypertension or initial poor visual acuity did not impact outcomes.
Implications:
- Subthreshold laser photocoagulation is effective for DDME, with potentially slower but less damaging resolution.
- This method offers advantages by minimizing visual field effects and reducing post-treatment scarring.